7,395 press releases indexed under healthcare.
The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinical study in scope. SCOTTSDALE, Ariz., Sept. 8, 2026 /PRNewswire/ -- A July 2026 vote by the...
LOS ANGELES, CA - September 8, 2026 ( NEWMEDIAWIRE ) - VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience spanning global capital markets, investment banking, corporate finance, asset management and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company’s capital strategy, strategic opportunities and continued development of its proprietary BiTAC(R) technology platform and oncology pipeline. Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being a
FDA grants Rare Pediatric Disease Designation to QRX003 for Peeling Skin Syndrome, Quoin's second RPD and a potential second Priority Review Voucher
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) , a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that Elias A. Zerhouni, M.D., President and Vice Chairman, and Adam Logal, Senior Vice President and Chief Financial Officer, will participate in the Wells Fargo 21st Annual Healthcare Conference at the Encore Boston Harbor, including a fireside chat on Thursday, September 10, 2026, at 9:30 a.m. ET.
Clinical psychologist Claire Hillenbrand Sherman pairs Jungian theory with reflection, journaling, active imagination and creative exercises OLDENBURG, Ind., Sept. 8, 2026 /PRNewswire/ -- "Discover Wholeness with Carl Jung and His Red Book," by clinical psychologist Claire Hillenbrand...
As organizations across Puerto Rico and the Caribbean continue to face increasing environmental and operational challenges, preparedness remains a critical component of long-term resilience. From hurricanes and flooding to public health emergencies and workplace hazards, having the right plans and professional support in place can make a significant difference in how quickly operations recover after a disruptive event. - - This September marks the 22nd annual National Preparedness Month (NP... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=360177
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2026) - BioVaxys Technology Corp. (OTC Pink: BVAXF) (CSE: BIOV) (FSE: 5LB), ("BioVaxys" or the "Company") a clinical-stage biopharmaceutical company focused on the development of durable, single-dose, vaccines for safe, scalable, and long-lasting immune protection in oncology, infectious disease, and immune dysfunctions, is pleased to announce its participation at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences...
(PR-inside.com) AUSTIN, TX / ACCESS Newswire / September 8, 2026 / Have you ever felt like your own body is working against you no matter how hard you try to shed stubborn weight? Millions of men and women wake up every day feeling exhausted, struggling with sudden energy crashes right after meals, and fighting relentless late-night cravings that willpower alone just cannot stop. For years, doctors and health experts have pointed to berberine as a breakthrough natural answer for managing blood sugar and kicking metabolism into high gear. However, traditional berberine pills and capsules often come with a heavy price: stomach cramps, ..
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 8, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SELLAS Life Sciences Group, Inc. ("SELLAS" or "the Company") (NASDAQ:SLS). Investors who purchased SELLAS securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/sellas-life-sciences-group-inc-sls-class_action_lawsuit. SELLAS Investigation Details On August 28, 2026, a news site reported that the Company's phase 3 clinical trial for Galinpepimut-S (GPS) had reached its 80th patient death, a pre-specified event that was to trigger the release of results for the clinical trial. However, as of ..
The Canadian astronaut and women's health expert will appear together on stage as a couple, joining Margaret Atwood, Lord David Cameron, Tyler Cowen, and leading voices shaping the future of energy CALGARY, AB, Sept. 8, 2026 /PRNewswire/ -- Energy Disruptors: UNITE has announced Artemis...
Collaboration will explore nutrition as a key driver of cardiovascular health through collaborative research led by Dr. Harold Schmitz AUSTIN, Texas, Sept. 8, 2026 /PRNewswire/ -- Humann, the Austin-based cardiovascular health supplement company, continued its legacy of engaging with...
SALT LAKE CITY, Sept. 8, 2026 /PRNewswire/ -- An extensive, first-of-its-kind research study by ARUP Laboratories clarifies the clinical value of atypical findings from prenatal cell-free DNA (cfDNA) screening and their impact on pregnancy outcomes. The study, which investigated the...